Quantcast

Latest Lundbeck Stories

2010-06-15 05:00:00

MINNEAPOLIS, June 15 /PRNewswire/ -- Orasi Medical® today announced that it has entered an agreement with H. Lundbeck A/S (Lundbeck) to study the effect of Lundbeck central nervous system (CNS) compounds on the human brain. (Logo: http://photos.prnewswire.com/prnh/20100615/CG19932LOGO) (Logo: http://www.newscom.com/cgi-bin/prnh/20100615/CG19932LOGO) With the average time to bring a CNS drug to market exceeding 12 years - and only 7 percent of neurological drugs making...

2009-10-09 08:00:00

DEERFIELD, Ill., Oct. 9 /PRNewswire/ -- The Huntington's Disease Society of America (HDSA) recognized Lundbeck last night with the Marjorie Guthrie Leadership Award for the company's steadfast commitment to the Huntington's disease (HD) community and for making a meaningful contribution to patients and families impacted by HD across the country. Lundbeck was honored at the 13th Annual HDSA Guthrie Awards Dinner celebration in New York. The award is bestowed annually to a corporate...

2009-08-31 07:00:00

DEERFIELD, Ill., Aug. 31 /PRNewswire/ -- Chicago-based Lundbeck Inc. was recently recognized with the Award of Excellence in Corporate Achievement by the Illinois Chapter of the Huntington's Disease Society of America (HDSA) for the company's significant contributions to the Huntington's disease (HD) community and making a meaningful contribution to the lives of people in the state of Illinois. The award was presented this past Friday at the fifth annual Celebration of Hope Dinner, chaired...

2009-07-10 08:15:00

NEW YORK, July 10, 2009 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX) and its wholly-owned subsidiary, Forest Laboratories Holdings, Ltd. (collectively, "Forest"), and H. Lundbeck A/S ("Lundbeck") announced today that they have entered into a settlement agreement with Sun Pharmaceutical Industries Ltd. ("Sun Pharma", a reference that includes its 100% subsidiaries) and Caraco Pharmaceutical Laboratories, Ltd. ("Caraco"), regarding pending patent infringement disputes...

2009-03-19 19:01:00

COPENHAGEN, March 20 /PRNewswire/ -- - On Average a Quarter of Europeans Surveyed From UK, Portugal, France, Germany, Czech Republic, Hungary and Poland Claim Worsening Quality of Sleep Thanks to the Economy(1) - Portuguese are Most Affected, With 42% Making the Admission, Compared to 17% of the UK(1) - 66% of European Adults on Average Have Experienced Problems Sleeping Over the Last 12 Months, but Only 19% of These Have Visited the Doctor(1) - Debilitating Next-Day...

2008-09-15 09:00:58

Lundbeck has announced that the FDA has completed the initial check for completeness and accepted the new drug application on Serdolect for the treatment of schizophrenia for review. Lundbeck said that this is the first new drug application (NDA) submitted in the US by the company, and it follows the launch of Serdolect in Europe, South and Central America, Asia and the Middle East. According to the company, Serdolect is an effective antipsychotic drug for the treatment of schizophrenia...

2008-07-15 06:00:57

Clinical Data, Inc. (NASDAQ:CLDA) a leader in the development of targeted therapeutics and predictive tests from its growing portfolio of proprietary genetic biomarkers, announced today that its Cogenics(R) division has entered into a Scientific Research & Development Agreement with H. Lundbeck A/S to support its ongoing clinical studies with genotyping solutions on a global basis. Lundbeck is an international pharmaceutical company engaged in the research and development, production,...

2008-06-18 09:01:19

WALTHAM, Mass., June 18 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, reports that Lundbeck acquired European marketing rights to Myriad Genetics' Flurizan in May of 2008 in a timely move as its own Namenda/Ebixa faces patent expiry in 2014. First-to-market advantage among disease-modifying drugs combined with a positive safety profile, positions Flurizan to be received favorably among physicians and...

2005-11-14 10:57:52

COPENHAGEN (Reuters) - Danish pharmaceutical group Lundbeck said on Monday that two Phase III studies had shown its anti-depressant Cipralex to be effective in treatment of obsessive-compulsive disorder (OCD). Cirpralex, sold in the United States as Lexapro by Forest Laboratories, is approved for the treatment of depression, panic disorder, social anxiety disorder and generalized anxiety disorder. Lundbeck will file for approval of the drug's use for OCD in the European Union in the...


Word of the Day
tessitura
  • The prevailing range of a vocal or instrumental part, within which most of the tones lie.
This word is Italian in origin and comes from the Latin 'textura,' web, structure.